EGFR and cancer: These data suggested that β-Catenin mediated stem-cell like properties of cancer cells harboring dual EGFR-activating mutation and T790M mutation may contribute to the activation of cell growth, proliferation, and the progression of disease; therefore, such research findings could explain the worse RFS in patients with NSCLC harboring concomitant preT790M.